SAFETY AND EFFICACY OF PTK787/ZK222584 IN PATIENTS WITH NEUROENDOCRINE CANCER

PTK787/ZK222584 在神经内分泌癌患者中的安全性和有效性

• 批准号: 7376335
• 负责人: LOWELL B ANTHONY
• 金额: $ 0.31万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376335
• 关键词: SAFETY; EFFICACY; PTK787; ZK222584; PATIENTS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objective: To evaluate the efficacy of PTK787/ZK222584 in subjects with metastatic neuroendocrine tumors that have evidence of progressive disease or an increase in disease related syndrome symptoms as evidence by control in biochemical markers. Secondary Objectives: To assess the safety and tolerability of PTK787/ZK222584 in subjects with metastatic neuroendocrine disease who are receiving octreotide therapy. To assess the effect of PTK787/ZK222584 on tumor response and duration of response using RECIST criteria. To assess the overal quality of life of subjects while receiving PTK787/ZK22584 in conjunction with octreotide therapy. To assess the ability of PTK787/ZK222584 to control disease related symptoms. To assess changes in the Octreoscan attributable to PTK787/ZK222584.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。主要目的：评价PTK 787/ZK 222584在转移性神经内分泌肿瘤受试者中的疗效，这些受试者有疾病进展或疾病相关综合征症状增加的证据，作为生化标志物对照的证据。 次要目的：评估PTK 787/ZK 222584在接受奥曲肽治疗的转移性神经内分泌疾病受试者中的安全性和耐受性。 使用RECIST标准评估PTK 787/ZK 222584对肿瘤缓解和缓解持续时间的影响。 评估接受PTK 787/ZK 22584联合奥曲肽治疗的受试者的总体生活质量。 评估PTK 787/ZK 222584控制疾病相关症状的能力。 评估归因于PTK 787/ZK 222584的Octreoscan变化。